Not Medicare Enrolled

Dr. Peter McCullough, MD, MPH

Cardiovascular Disease · Dallas, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Consulting-driven
3409 WORTH ST STE 500, Dallas, TX 75246
2148412000
In practice since 2006 (20 years)
NPI: 1386604700 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. McCullough from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. McCullough? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. McCullough

Dr. Peter McCullough is a cardiovascular disease in Dallas, TX, with 20 years in practice. Based on federal Medicare data, Dr. McCullough performed 36 Medicare services across 36 unique beneficiaries.

Between the years covered by Open Payments, Dr. McCullough received a total of $969,658 from 60 pharmaceutical and/or device companies across 1069 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. McCullough is High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ 36 Medicare services$ $969,658 industry payments

Medicare Practice Summary

Medicare Utilization ↗
36
Medicare services
Bottom 2% in TX for cardiovascular disease
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
36
Unique beneficiaries
$53
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Office visit, established patient (20-29 min)22$33$150
Office visit, established patient (30-39 min)14$85$220
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$969,658
Total received (2018-2024)
Avg $138,523/year across 7 years
Top 0% in TX for cardiovascular disease
60
Companies
1,069
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$491,279 (50.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$415,204 (42.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$63,175 (6.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$405
2023
$3,239
2022
$20,802
2021
$93,178
2020
$183,831
2019
$362,280
2018
$305,924

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$181,973
SANOFI-AVENTIS U.S. LLC
$116,500
Amgen Inc.
$101,180
Merck Sharp & Dohme Corporation
$57,892
Edwards Lifesciences Corporation
$45,989
Novo Nordisk Inc
$43,336
Regeneron Healthcare Solutions, Inc.
$40,635
Janssen Pharmaceuticals, Inc
$40,180
Novo Nordisk AS
$40,000
Bayer HealthCare Pharmaceuticals Inc.
$35,983
AstraZeneca AB
$22,740
AKEBIA THERAPEUTICS INC
$17,980
SANOFI US SERVICES INC.
$17,674
NxStage Medical, Inc.
$17,664
Otsuka Pharmaceutical Co., Ltd.
$17,364
Lilly USA, LLC
$15,336
GE HEALTHCARE
$15,313
Abbott Laboratories
$15,113
Eli Lilly and Company
$14,700
Boehringer Ingelheim Pharmaceuticals, Inc.
$14,142
Janssen Scientific Affairs, LLC
$13,390
AstraZeneca UK Limited
$12,159
Mallinckrodt Hospital Products Inc.
$10,800
Janssen Research & Development, LLC
$10,000
Instrumentation Laboratory Company
$6,328
Aegerion Pharmaceuticals, Inc.
$6,044
BAXTER HEALTHCARE
$5,996
Boehringer Ingelheim International GmbH
$5,470
Quidel Corporation
$4,943
Mallinckrodt Enterprises LLC
$3,741
Chiesi USA, Inc.
$3,653
Rockwell Medical, Inc.
$3,000
Regeneron Pharmaceuticals, Inc.
$2,758
Esperion Therapeutics, Inc.
$2,394
CHF Solutions, Inc
$2,121
Novartis Pharma AG
$1,255
Medicure Pharma Inc.
$701
Boehringer Ingelheim Pharma GmbH & Co.KG
$630
Keryx Biopharmaceuticals, Inc.
$450
Novartis Pharmaceuticals Corporation
$419
Merck Sharp & Dohme LLC
$333
E.R. Squibb & Sons, L.L.C.
$250
Corium, LLC
$225
Amarin Pharma Inc.
$205
GE Healthcare
$133
Amicus Therapeutics, Inc.
$79
Alnylam Pharmaceuticals Inc.
$77
Lexicon Pharmaceuticals, Inc.
$64
Potrero Medical, Inc.
$50
ABBVIE INC.
$47
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$37
ABIOMED
$37
GlaxoSmithKline, LLC.
$35
Corcept Therapeutics
$33
Amryt Pharma Holdings Ltd
$25
Takeda Pharmaceuticals U.S.A., Inc.
$22
IDORSIA PHARMACEUTICALS US INC
$17
Azurity Pharmaceuticals, Inc.
$16
Lantheus Medical Imaging, Inc.
$16
PFIZER INC.
$12
Top 3 companies account for 41.2% of total payments
Associated products mentioned in payments ›
ACTHAR · ACZ885M · AREXVY · Aquadex · Architect CK-MB · Architect system · Auryxia · Azstarys · BELSOMRA · BRILINTA · CAMZYOS · CHANTIX · CardioMEMS HF System · Corlanor · DEFINITY · EDARBYCLOR · ELIQUIS · ENTRESTO · EVENITY · FARXIGA · GALAFOLD · GZ402671 · HeartMate · INVOKANA · Impella · JARDIANCE · JUXTAPID · Juxtapid · KENGREAL · Kerendia · Korlym · LEQVIO · LOKELMA · LifeVest · MOUNJARO · NEXLETOL · NEXLIZET · NXSTAGE SYSTEM ONE · Non-Covered · ONPATTRO · Otezla · Ozempic · PRADAXA · PRALUENT · PRALUENT ALIROCUMAB INJECTION · QULIPTA · QUVIVIQ · RYBELSUS · Renal - PD · Repatha · Rybelsus · STEGLATRO · SYSTEM ONE · System One · TRELEGY ELLIPTA · TRIFERIC · TRINTELLIX · TZIELD · UBRELVY · VERQUVO · VISIPAQUE · Vascepa · Victoza · Wegovy · XARELTO · ZYPITAMAG · ZYPITAMAG (pitavastatin)
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (51%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 0% for cardiovascular disease in TX.

Equivalent to $2,693,494 per 100 Medicare services performed
Looking for a cardiovascular disease in Dallas?
Compare cardiovascular diseases in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse cardiovascular diseases nearby

Geographic Context

Cardiovascular Diseases within 10 mi
292
Per 100K population
11.2
County median income
$74,149
Nearest hospital
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment— Not enrolledN/A
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. McCullough is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (consulting-driven, top 0%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. McCullough experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. McCullough performed 22 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. McCullough receive payments from pharmaceutical companies?
Yes. Dr. McCullough received a total of $969,658 from 60 companies across 1,069 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. McCullough's costs compare to other cardiovascular diseases in Dallas?
Dr. McCullough's average Medicare payment per service is $53. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently High for Dr. McCullough) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →